Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study

Published:2018-02 Issue: Volume:90 Page:92-101
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Dackus G.M.H.E.,Jóźwiak K.,Sonke G.S.,van der Wall E.,van Diest P.J.,Hauptmann M.,Siesling S.,Linn S.C.

Funder

The Netherlands Organization for Health Research and Development

A Sisters Hope

De Vrienden van UMC Utrecht

Roche

Amgen

AstraZeneca

Bristol-Myers Squibb

Genentech

Sanofi

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference22 articles.

1. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004;Winer;J Clin Oncol,2005

2. Adjuvant ovarian suppression in premenopausal breast cancer;Francis;N Engl J Med,2015

3. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer;Pagani;N Engl J Med,2014

4. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen;Hurtado;Nature,2008

5. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu;Benz;Breast Cancer Res Treat,1992

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer;Cancer Medicine;2024-06

2. Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial;npj Breast Cancer;2023-02-04

3. Adjuvant aromatase inhibitor therapy and early markers for cardiovascular disease in breast cancer survivors;Breast Cancer Research and Treatment;2022-10-01

4. Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial;2022-09-23

5. Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients;JNCI: Journal of the National Cancer Institute;2021-06-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3